Neuro-Oncology

Article	Citations
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary	5698
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	1269
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	944
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019	641
EANO guideline on the diagnosis and management of meningiomas	311
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter	225
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial	205
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020	168
Epidemiology of brain metastases and leptomeningeal disease	167
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	134
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications	127
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis	122
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial	121
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma	117
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group	97
A molecularly integrated grade for meningioma	94
Associations of meningioma molecular subgroup and tumor recurrence	94
Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance	92
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification	91
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study	91
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)	89
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR	88
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group	85
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors	80
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults	80

MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors	78
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors	74
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery	74
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions	73
Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas	72
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification	70
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)	69
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma	69
Brain metastasis detection using machine learning: a systematic review and meta-analysis	69
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank	68
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity	67
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors	64
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions	63
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study	63
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma	63
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma	62
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)	58
A serum-based DNA methylation assay provides accurate detection of glioma	57
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications	55
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial	55
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas	54
The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions	53
TGF-β promotes microtube formation in glioblastoma through thrombospondin 1	53
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma	52
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial	52
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)	52
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylatedMGMTglioblastoma: the VERTU study	51
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas	51
Loss of H3K27me3 in meningiomas	50
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q	49
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models	49
Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study	48
Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning	47
Management of neurofibromatosis type 1-associated plexiform neurofibromas	47
Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients	45
Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy	45
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma	45
Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics	45
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models	43
Establishment of patient-derived organoid models of lower-grade glioma	43
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results	42
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma	41
Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study	41
The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors	41
An international multicenter matched cohort analysis of incidental meningioma progression during active surveillance or after stereotactic radiosurgery: the IMPASSE study	40
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection	40
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma	40
MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma	40
The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis	40
Histiocytosis and the nervous system: from diagnosis to targeted therapies	39

Identification of diverse tumor endothelial cell populations in malignant glioma	39
MGMTpromoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review	39
Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition	39
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus	39
Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells	38
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid phar	38
Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas	38
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma	38
DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology	38
The impact of socioeconomic status (SES) on cognitive outcomes following radiotherapy for pediatric brain tumors: a prospective, longitudinal trial	37
Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017	36
H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort	36
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant	36
Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine	36
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies	36
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma	36
Distinct metabolic hallmarks of WHO classified adult glioma subtypes	36
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas	35
Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors	35
Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors	35
IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation	35
Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: A longitudinal, within-patient design study	34
The genetic landscape of choroid plexus tumors in children and adults	34
Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors	34
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report	34
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial	34
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse	34
Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO	34
PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2	34
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States	33
The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis	33
National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States	33
Corrigendum to: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	33
Newly established patient-derived organoid model of intracranial meningioma	33
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review	32
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival	32
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children’s Oncology Group study	32
The natural history of vestibular schwannoma growth—prospective 40-year data from an unselected national cohort	32
EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors	31
Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative properties	31
Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5	31
The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas	31
The use of external control data for predictions and futility interim analyses in clinical trials	30
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib	30
Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma	29
Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling	28
PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma	28
Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a lon	28
Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts	28
Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET	28
EPEN-54. ACNS0831, PHASE III RANDOMIZED TRIAL OF POST-RADIATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED EPENDYMOMA AGES 1 TO 21 YEARS	28
Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of glioblastoma	27
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline	27
Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features	27
Randomized multi-reader evaluation of automated detection and segmentation of brain tumors in stereotactic radiosurgery with deep neural networks	27
Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study	27
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033	27
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma	27
Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis	27
Palliative care and end-of-life care in adults with malignant brain tumors	27
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)	26
The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study	26
Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas	26
Population-based estimates of survival among elderly patients with brain metastases	26
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas	26
Extracellular vesicles: The key for precision medicine in glioblastoma	25
DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients	25
Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up	25
Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging	25
Long-term natural history and patterns of sporadic vestibular schwannoma growth: A multi-institutional volumetric analysis of 952 patients	25
Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma	25
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma	25
The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas	24
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy	24
Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma	24
Tumor cell network integration in glioma represents a stemness feature	24
Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas	24
Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning	24
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma	24
A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes	24

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort	24
T lymphocytes as dynamic regulators of glioma pathobiology	23
Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution	23
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma	23
Telomerase as a therapeutic target in glioblastoma	23
Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study	23
DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma	23
Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study	23
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications	23
LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)	22
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors	22
MEVITEM—a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation	22
Spatial concordance of DNA methylation classification in diffuse glioma	22
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles	22
A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma	22
Relationship between genetically determined telomere length and glioma risk	21
Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas	21
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma	21
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study	21
RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth	21
The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3)	21
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models	21
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548	20
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival	20
Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study	20
Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story	20
BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma	20
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions	20
USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5	20
Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group	20
ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling	20
Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases	19
Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma	19
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma	19
Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models	19
Heterogeneity and excitability of BRAF V600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss	19
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondr	19
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?	19
A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act	19
Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group	19
Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups	19
Glioblastoma scRNA-seq shows treatment-induced, immune-dependent increase in mesenchymal cancer cells and structural variants in distal neural stem cells	18
Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification	18
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma	18
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma	18
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity	18
EGFR, the Lazarus target for precision oncology in glioblastoma	18
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients	17
SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort—A BIOMECA Consortium Study	17
Elucidating the neurological mechanism of the FLASH effect in juvenile mice exposed to hypofractionated radiotherapy	17
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)	17
Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression	17
What is the burden of proof for tumor mutational burden in gliomas?	17
Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908	17
Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease	17
Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases	17
The incidence of major subtypes of primary brain tumors in adults in England 1995-2017	17
Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts	17
Pediatric low-grade glioma: State-of-the-art and ongoing challenges	17
Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study	16
A comparative integrated multi-omics analysis identifies CA2 as a novel target for chordoma	16
Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3)	16
Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial	15
Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome	15
Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening	15
Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades	15
Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas	15
Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study	15
STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma	15
Metformin effects on brain development following cranial irradiation in a mouse model	15
Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells	15
Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy	15
TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?	15
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making	15
Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary	15
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial	14
iGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium	14
Outcomes of intracranial germinoma—A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies	14
Limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: long-term results from the RT1 protocol	14
Spliceosome-regulated RSRP1-dependent NF-κB activation promotes the glioblastoma mesenchymal phenotype	14
Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma	14
BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models	14
Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma	14
Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors	14
Nestin+/CD31+ cells in the hypoxic perivascular niche regulate glioblastoma chemoresistance by upregulating JAG1 and DLL4	14
Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes	14
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials	14
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis	14
Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics	14
Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma	13
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma	13
Diagnostic potential of extracellular vesicles in meningioma patients	13
Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis	13
Recent advances and new discoveries in the pipeline of the treatment of primary spinal tumors and spinal metastases: a scoping review of registered clinical studies from 2000 to 2020	13
Patient-derived orthotopic xenograft models of medulloblastoma lack a functional blood-brain barrier	13